Markets

  • Advancing research and development of klotho protein for age-related therapeutics

    Klothea Bio has secured funding from Longevitytech.fund to pioneer breakthrough treatments for metabolic syndrome and several age-related diseases. Advantage Therapeutics, which develops therapies targeting age-related diseases, has announced the formation of its new subsidiary, Klothea Bio, which will focus exclusively on the research and development of klotho-based therapies to prevent and treat various age-associated conditions. [...]

  • Global coalition’s plan to slash chance of death before 70 in half

    A global coalition of experts has drawn up a roadmap for how any country can cut the chance of premature death for its citizens in half by 2050. Since 1970, 37 countries have cut the probability of their citizens dying before they reach age 70 in half. But the new report argues that this goal [...]

  • Two million older people in the UK have unmet need for social care

    A report from charity Age UK has found that two million older people are struggling due to insufficient access to high quality NHS treatment and social care, and that the system is currently under-prepared for population ageing. New analysis carried out by Age UK has found that 2 million older people in England are now [...]

  • Children’s consortium collaborates with European consortium to accelerate innovation

    To support the global need for innovation in paediatric medical device development, the Alliance for Pediatric Device Innovation (APDI), a consortium funded by the U.S. Food and Drug Administration (FDA) and led by Children’s National Hospital, is partnering with DeCODe, a new European Commission-funded device consortium, to advance medical technologies that benefit children. DeCODe was [...]

  • Phase 3 clinical trial expected for Stargardt Macular Degeneration treatment

    Nanoscope Therapeutics has announced the expected advancement of MCO-010 for the treatment of Stargardt Macular Degeneration (SMD) to a Phase 3 registrational trial following a productive end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA).  Nanoscope Therapeutics has said that the FDA provided clear input on the proposed Phase 3 registrational trial [...]

  • Fast Track Designation granted for imaging agent that evaluates neurodegenerative conditions

    Life Molecular Imaging (LMI) has announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to [18F]PI-2620 Injection, an investigational PET imaging agent targeting tau neurofibrillary tangles, for clinical development in neurodegenerative conditions. The neurodegenerative conditions include in Alzheimer's disease (AD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). The FDA's Fast [...]

  • On a mission to show that hearing loss is not inevitable

    The world’s largest investigation into the effectiveness of hearing training kicks off this week - as part of a movement to prove that hearing loss is not an inevitable part of ageing. The research project aims to attract a minimum of 10,000 participants to better understand how hearing training impacts auditory processing skills like speech comprehension and [...]

  • UK body calls for more ageing research backing

    The British Society for Research on Ageing (BSRA) is calling for more public backing in the UK for research to help people stay healthier for longer, as an alternative to charities that support research on diseases. The greatest risk factor for disease is ageing, but we have very little charitable support for research into how [...]

  • Agetech World podcast: Why it’s time to stop talking about generations

    From post-war baby boomers to the current Generation Alphas, stage-of-life labels beloved of cultural commentators, researchers and marketers, will soon be a thing of the past, predicts the head of the globally influential UK National Innovation Centre for Ageing. Researcher, teacher, writer and TEDx speaker, Professor Nic Palmarini, has told the latest Agetech World podcast [...]

  • LongeVC: “Longevity will never be a magic pill that will make us younger”

    LongeVC CEO and founder Garri Zmudze speaks about the firm’s mission to create an ageless future with its support for innovative longevity tech companies.  Investment firm, LongeVC has a portfolio of companies across the likes of consumer health, AI for drug discovery, biotech and gene therapy. Connecting them all is a shared mission to create [...]